"Ki-1 Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A member of the tumor necrosis factor receptor superfamily that may play a role in the regulation of NF-KAPPA B and APOPTOSIS. It is found on activated T-LYMPHOCYTES; B-LYMPHOCYTES; NEUTROPHILS; EOSINOPHILS; MAST CELLS and NK CELLS. Overexpression of the Ki-1 antigen in hematopoietic malignancies make it clinically useful as a biological tumor marker. Signaling of the receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.
| Descriptor ID |
D017730
|
| MeSH Number(s) |
D12.776.543.750.705.852.760.072 D23.050.285.025 D23.101.140.055
|
| Concept/Terms |
Ki-1 Antigen- Ki-1 Antigen
- Antigen, Ki-1
- Ki 1 Antigen
- CD30 Antigens
- Antigens, CD30
- Ber-H2 Antigen
- Antigen, Ber-H2
- Ber H2 Antigen
- TNFRSF8 Receptor
- Receptor, TNFRSF8
- Antigens, Ki-1
- Antigens, Ki 1
- Ki-1 Antigens
- Ki 1 Antigens
- Tumor Necrosis Factor Receptor Superfamily, Member 8
- CD30 Antigen
- Antigen, CD30
- Ber-H2 Antigens
- Antigens, Ber-H2
- Ber H2 Antigens
|
Below are MeSH descriptors whose meaning is more general than "Ki-1 Antigen".
Below are MeSH descriptors whose meaning is more specific than "Ki-1 Antigen".
This graph shows the total number of publications written about "Ki-1 Antigen" by people in this website by year, and whether "Ki-1 Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 2 | 0 | 2 |
| 2014 | 0 | 1 | 1 |
| 2017 | 1 | 1 | 2 |
| 2020 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
| 2024 | 1 | 0 | 1 |
| 2026 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ki-1 Antigen" by people in Profiles.
-
Tumor-specific immune responses and biomarkers in pediatric patients with high-risk Hodgkin lymphoma. Blood Adv. 2026 Jan 13; 10(1):183-191.
-
Novel OX40 and 4-1BB derived spacers enhance CD30 CAR activity and safety in CD30 positive lymphoma models. Mol Ther. 2024 10 02; 32(10):3504-3521.
-
Chimeric Antigen Receptor T Cells in Hodgkin and T-Cell Lymphomas. Hematol Oncol Clin North Am. 2023 12; 37(6):1107-1124.
-
Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood-Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies. Clin Cancer Res. 2021 07 01; 27(13):3744-3756.
-
Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma. J Clin Oncol. 2020 11 10; 38(32):3794-3804.
-
Brentuximab-vedotin maintenance following chemotherapy without irradiation for primary intracranial embryonal carcinoma in down syndrome. Childs Nerv Syst. 2018 04; 34(4):777-780.
-
Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. J Clin Invest. 2017 Sep 01; 127(9):3462-3471.
-
A novel recurrent NPM1-TYK2 gene fusion in cutaneous CD30-positive lymphoproliferative disorders. Blood. 2014 Dec 11; 124(25):3768-71.
-
Specific and sensitive tumor imaging using biostable oligonucleotide aptamer probes. Theranostics. 2014; 4(9):945-52.
-
Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries. Clin Cancer Res. 2014 May 01; 20(9):2338-49.